Economic implications of an evidence-based sepsis protocol: Can we improve outcomes and lower costs?

Critical Care Medicine

Volumn 35, Issue 5, 2007, Pages 1257-1262

  Shorr, Andrew F ^a,b   Micek, Scott T ^c   Jackson Jr , William L ^d   Kollef, Marin H ^e  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

^d Health First   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cost; Economics; Outcomes; Protocol; Sepsis

Indexed keywords

ANTIBIOTIC AGENT;

ACCURACY; ADULT; AGED; COST BENEFIT ANALYSIS; COST OF ILLNESS; EMERGENCY WARD; FEMALE; FLUID RESUSCITATION; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; REVIEW; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; TEACHING HOSPITAL; TERTIARY HEALTH CARE; TREATMENT OUTCOME;

EID: 34247336921     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000261886.65063.CC     Document Type: Article

References (21)

1. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554
2. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
3. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301-1308
4. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
5. van den Berghe G, Wouters P, Weekers F, et al: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-1367
6. Rivers E, Nguyen B, Havstad S, et al: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377
7. Dellinger RP, Carlet JM, Masur H, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873
8. Wood KA, Angus DC: Pharmacoeconomic implications of new therapies in sepsis. Pharmacoeconomics 2004; 22:895-906
9. Burchardi H, Schneider H: Economic aspects of severe sepsis: A review of intensive care unit costs, cost of illness and cost effectiveness of therapy. Pharmacoeconomics 2004; 22:793-813
10. Zack JE, Garrison T, Trovillion E, et al: Effect of an education program aimed at reducing the occurrence of ventilator-associated pneumonia. Crit Care Med 2002; 30:2407-2412
11. Shorr AF, Humphreys CW, Helman DL: New choices for central venous catheters: Potential financial implications. Chest 2003; 124:275-284
12. Gao F, Melody T, Daniels DF, et al: The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: A prospective observational study. Crit Care 2005; 9:R764-R770
13. Shapiro NI, Howell MD, Talmor D, et al: Implementation and outcomes of the Multiple Urgent Sepsis Therapies (MUST) protocol. Crit Care Med 2006; 34:1025-1032
14. Micek ST, Roubinian N, Heuring T, et al: A before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med 2006; 34:2707-2713
15. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
16. Schulgen G, Kropec A, Kappstein I, et al: Estimation of extra hospital stay attributable to nosocomial infections: heterogeneity and timing of events. J Clin Epidemiol 2000; 53:409-417
17. Korkeila M, Ruokonen E, Takala J: Costs of care, long-term prognosis and quality of life in patients requiring renal replacement therapy during intensive care. Intensive Care Med 2000; 26:1824-1831
18. Hamel MB, Phillips RS, Davis RB, et al: Outcomes and cost-effectiveness of ventilator support and aggressive care for patients with acute respiratory failure due to pneumonia or acute respiratory distress syndrome. Am J Med 2000; 109:614-620
19. Angus DC, Linde-Zwirble WT, Clermont G, et al: Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003; 31:1-11
20. Manns BJ, Lee H, Doig CJ, et al: An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347:993-1000
21. Nguyen HB, Corbett SW, Menes K, et al: Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department. Acad Emerg Med 2006; 13:109-113